Besifloxacina (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Besifloxacina" in Italian language version.

refsWebsite

Global rank Italian rank

7nih.gov

4^th place

9^th place

6doi.org

2^nd place

7^th place

2oadoi.org

799^th place

22^nd place

1asm.org

3,555^th place

2,382^nd place

1wkhealth.com

low place

7,876^th place

1fda.gov

447^th place

644^th place

asm.org

aac.asm.org

Haas W, Pillar CM, Zurenko GE, Lee JC, Brunner LS, Morris TW, Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria, in Antimicrobial Agents and Chemotherapy, vol. 53, n. 8, Agosto 2009, pp. 3552–60, DOI:10.1128/AAC.00418-09, PMC 2715578, PMID 19506065. URL consultato il 6 gennaio 2015.

doi.org

dx.doi.org

Ward KW, Lepage JF, Driot JY, Nonclinical pharmacodynamics, pharmacokinetics, and safety of BOL-303224-A, a novel fluoroquinolone antimicrobial agent for topical ophthalmic use, in J Ocul Pharmacol Ther, vol. 23, n. 3, Giugno 2007, pp. 243–56, DOI:10.1089/jop.2006.0137, PMID 17593008. URL consultato il 6 gennaio 2015.
Haas W, Pillar CM, Zurenko GE, Lee JC, Brunner LS, Morris TW, Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria, in Antimicrobial Agents and Chemotherapy, vol. 53, n. 8, Agosto 2009, pp. 3552–60, DOI:10.1128/AAC.00418-09, PMC 2715578, PMID 19506065. URL consultato il 6 gennaio 2015.
Zhang JZ, Ward KW, Besifloxacin, a novel fluoroquinolone antimicrobial agent, exhibits potent inhibition of pro-inflammatory cytokines in human THP-1 monocytes, in J. Antimicrob. Chemother., vol. 61, n. 1, gennaio 2008, pp. 111–6, DOI:10.1093/jac/dkm398, PMID 17965029. URL consultato il 6 gennaio 2015.
Malhotra R, Ackerman S, Gearinger LS, Morris TW, Allaire C, The safety of besifloxacin ophthalmic suspension 0.6 % used three times daily for 7 days in the treatment of bacterial conjunctivitis, in Drugs in R&D, vol. 13, n. 4, Dicembre 2013, pp. 243–52, DOI:10.1007/s40268-013-0029-1, PMC 3851703, PMID 24142473. URL consultato il 6 gennaio 2015.
Majmudar PA, Clinch TE, Safety of besifloxacin ophthalmic suspension 0.6% in cataract and LASIK surgery patients ^{[collegamento interrotto]}, in Cornea, vol. 33, n. 5, Maggio 2014, pp. 457–62, DOI:10.1097/ICO.0000000000000098, PMC 4195578, PMID 24637269. URL consultato il 6 gennaio 2015.
Nielsen SA, McDonald MB, Majmudar PA, Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients, in Clinical Ophthalmology (Auckland, N.Z.), vol. 7, 2013, pp. 149–56, DOI:10.2147/OPTH.S38279, PMC 3552478, PMID 23355771. URL consultato il 6 gennaio 2015.

fda.gov

Onyeka Otugo, Olabode Ogundare, Christopher Vaughan, Emmanuel Fadiran, Leyla Sahin, Consistency of Pregnancy Labeling Across Different Therapeutic Classes (PDF), su fda.gov, Food and Drug Administration - Office of Women’s Health, 1979. URL consultato il 27 giugno 2013.

nih.gov

ncbi.nlm.nih.gov

Ward KW, Lepage JF, Driot JY, Nonclinical pharmacodynamics, pharmacokinetics, and safety of BOL-303224-A, a novel fluoroquinolone antimicrobial agent for topical ophthalmic use, in J Ocul Pharmacol Ther, vol. 23, n. 3, Giugno 2007, pp. 243–56, DOI:10.1089/jop.2006.0137, PMID 17593008. URL consultato il 6 gennaio 2015.
Haas W, Pillar CM, Zurenko GE, Lee JC, Brunner LS, Morris TW, Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria, in Antimicrobial Agents and Chemotherapy, vol. 53, n. 8, Agosto 2009, pp. 3552–60, DOI:10.1128/AAC.00418-09, PMC 2715578, PMID 19506065. URL consultato il 6 gennaio 2015.
Zhang JZ, Ward KW, Besifloxacin, a novel fluoroquinolone antimicrobial agent, exhibits potent inhibition of pro-inflammatory cytokines in human THP-1 monocytes, in J. Antimicrob. Chemother., vol. 61, n. 1, gennaio 2008, pp. 111–6, DOI:10.1093/jac/dkm398, PMID 17965029. URL consultato il 6 gennaio 2015.
Malhotra R, Ackerman S, Gearinger LS, Morris TW, Allaire C, The safety of besifloxacin ophthalmic suspension 0.6 % used three times daily for 7 days in the treatment of bacterial conjunctivitis, in Drugs in R&D, vol. 13, n. 4, Dicembre 2013, pp. 243–52, DOI:10.1007/s40268-013-0029-1, PMC 3851703, PMID 24142473. URL consultato il 6 gennaio 2015.
Majmudar PA, Clinch TE, Safety of besifloxacin ophthalmic suspension 0.6% in cataract and LASIK surgery patients ^{[collegamento interrotto]}, in Cornea, vol. 33, n. 5, Maggio 2014, pp. 457–62, DOI:10.1097/ICO.0000000000000098, PMC 4195578, PMID 24637269. URL consultato il 6 gennaio 2015.
Nielsen SA, McDonald MB, Majmudar PA, Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients, in Clinical Ophthalmology (Auckland, N.Z.), vol. 7, 2013, pp. 149–56, DOI:10.2147/OPTH.S38279, PMC 3552478, PMID 23355771. URL consultato il 6 gennaio 2015.
R. Sannerstedt, P. Lundborg; BR. Danielsson; I. Kihlström; G. Alván; B. Prame; E. Ridley, Drugs during pregnancy: an issue of risk classification and information to prescribers., in Drug Saf, vol. 14, n. 2, Feb 1996, pp. 69-77, PMID 8852521.

oadoi.org

Ward KW, Lepage JF, Driot JY, Nonclinical pharmacodynamics, pharmacokinetics, and safety of BOL-303224-A, a novel fluoroquinolone antimicrobial agent for topical ophthalmic use, in J Ocul Pharmacol Ther, vol. 23, n. 3, Giugno 2007, pp. 243–56, DOI:10.1089/jop.2006.0137, PMID 17593008. URL consultato il 6 gennaio 2015.
Zhang JZ, Ward KW, Besifloxacin, a novel fluoroquinolone antimicrobial agent, exhibits potent inhibition of pro-inflammatory cytokines in human THP-1 monocytes, in J. Antimicrob. Chemother., vol. 61, n. 1, gennaio 2008, pp. 111–6, DOI:10.1093/jac/dkm398, PMID 17965029. URL consultato il 6 gennaio 2015.

wkhealth.com

meta.wkhealth.com

Majmudar PA, Clinch TE, Safety of besifloxacin ophthalmic suspension 0.6% in cataract and LASIK surgery patients ^{[collegamento interrotto]}, in Cornea, vol. 33, n. 5, Maggio 2014, pp. 457–62, DOI:10.1097/ICO.0000000000000098, PMC 4195578, PMID 24637269. URL consultato il 6 gennaio 2015.